News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Genmab A/S Announces Pipeline and Technology Update
April 21, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COPENHAGEN, Denmark, April 21, 2010 (GLOBE NEWSWIRE) -- Summary: Genmab has announced a new pre-clinical antibody program, HuMax-cMet, as well as a novel next generation antibody technology.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Immunology and inflammation
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans
July 7, 2025
·
1 min read
·
Dan Samorodnitsky
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
·
8 min read
·
Tristan Manalac
Immuno-oncology
Four Therapies Hanging On in Troubled TIGIT Space
July 7, 2025
·
9 min read
·
Tristan Manalac
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
July 3, 2025
·
2 min read
·
Tristan Manalac
